Table 2 Summary of the genes that were up-regulated by doxorubicin treatment, including the log ratios
Samples with increased expression (n) | Gene symbol | Mean log ratio | Range of log ratio | Samples with decreased expression (n) | Mean log ratio | (Range of) log ratio |
|---|---|---|---|---|---|---|
15 | TNFRSF10B | 1.96 | 0.41/4.49 | 0 | - | - |
12 | CDKN1A | 1.85 | 0.59/4.10 | 1 | - | -0.99 |
12 | GADD45A | 1.44 | 0.58/2.88 | 1 | - | -0.59 |
12 | FAS | 1.36 | 0.27/3.87 | 1 | - | -0.28 |
12 | CD40 | 0.94 | 0.39/2.11 | 0 | - | - |
11 | PAWR | 1.16 | 0.33/2.51 | 1 | - | -1.25 |
11 | TNFAIP3 | 2.16 | 0.23/3.67 | 0 | - | - |
10 | NFKBIA | 2.04 | 0.43/3.34 | 2 | -0.57 | -0.45/-0.69 |
10 | IER3 | 3.81 | 0.71/6.08 | 2 | -0.60 | -0.36/-0.84 |
10 | PSEN1 | 0.84 | 0.23/1.61 | 2 | -0.46 | -0.46 |
10 | RIPK2 | 2.02 | 0.42/3.65 | 2 | -0.60 | -0.46/-0.74 |
10 | PEA15 | 0.61 | 0.23/0.96 | 1 | - | -0.68 |
10 | BCL2A1 | 2.18 | 1.03/5.08 | 1 | - | -0.98 |
10 | NGFB | 3.06 | 0.40/5.80 | 1 | - | -1.12 |
10 | BIRC3 | 2.06 | 0.63/3.23 | 1 | - | -0.93 |
10 | CD44 | 1.57 | 0.26/3.09 | 1 | - | -0.56 |
9 | MCL1 | 1.46 | 0.67/2.08 | 3 | -0.65 | -0.26/-1.21 |
9 | HSPA9 | 1.25 | 0.46/1.95 | 2 | -0.50 | -0.21/-0.79 |
9 | BTG1 | 0.77 | 0.31/1.50 | 1 | - | -1.06 |
9 | HSP90B1 | 0.80 | 0.21/1.10 | 0 | - | - |
9 | SQSTM1 | 2.03 | 0.27/3.23 | 0 | - | - |
9 | PPP1R15A | 3.16 | 0.65/4.40 | 0 | - | - |
9 | IRF1 | 1.38 | 0.60/2.94 | 0 | - | - |
9 | CYCS | 0.82 | 0.34/1.37 | 0 | - | - |
9 | MDM2 | 1.76 | 0.33/3.58 | 0 | - | - |